Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of BPM31510 with Vitamin K1 in Subjects with Newly Diagnosed Glioblastoma (GB)

Next Previous
X
Search
Trial Profile

A Study of BPM31510 with Vitamin K1 in Subjects with Newly Diagnosed Glioblastoma (GB)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ubidecarenone (Primary) ; Phytomenadione; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Berg Pharma; BPG Bio

    • Most Recent Events

    • 21 Nov 2024 According to a BPG Bio media release, Seema Nagpal, M.D., Clinical Professor of Neurology and Neurological Sciences at Stanford Medicine, is the principal investigator of the BPM31510 GBM phase 2b trial.
    • 21 Nov 2024 According to a BPG Bio media release, data from the study will be presented at the Society for Neuro-Oncology (SNO) 2024 Annual Meeting, taking place November 21-24, 2024, in Houston, Texas.
    • 12 Sep 2024 According to a BPG Bio media release, data from the study will be presented at the European Society for Medical Oncology (ESMO) Congress 2024, taking place September 13-17 in Barcelona.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top